Positive Results for AlzeCure’s Phase IIa clinical study in neuropathic pain with the non-opioid ACD440
LINK Medical, and AlzeCure® Pharma AB (publ) (FN STO: ALZCUR) announce the positive data results from the Phase IIa clinical study with the non-opioid drug candidate ACD440, which is developed against peripheral neuropathic pain